Cougar initiates Phase III prostate cancer trial
|
| The Phase III trial is a randomized, double-blind, placebo-controlled trial of CB7630 plus prednisone in patients with metastatic castration-resistant prostate cancer who have failed docetaxel-based chemotherapy. Similar to the patient populations in Cougar's Phase II trials COU-AA-003 and COU-AA-004, patients are allowed to have received up to two...more |
|
Osteoporosis a risk when taking steroids
|
What many of these patients may not know is that these drugs can put them at risk for steroid-induced osteoporosis.
"Steroids actually accelerate bone loss," said Dr. Mona Chitre of Excellus BlueCross BlueShield. "They decrease calcium absorption and they actually work by inhibiting the way our body and bones take in the calcium to make ...more |
|
The International Myeloma Foundation Says New Treatment Regimen for Older Patients Could Soon Be Approved in Europe
|
| “Thalidomide is the first of what are called the Novel Therapies that – along with VELCADE® and REVLIMID® - have changed the outlook for myeloma patients,” said Susie Novis, president and co-founder of the IMF. “Thalidomide is available in the United States, Australia, New Zealand and elsewhere now, and we would like all patients to have ...more |
|
Prednisone and Fractures
|
| When used properly, these drugs save lives and avert injury to bodily organs. They have a rapid onset of action, and profoundly affect many parts of the immune system as well as most other body systems. Corticosteroids are used to treat a variety of conditions such as vasculitis; arthritis; skin, blood, kidney, eye, thyroid, and intestinal disorder...more |
|
European Medicines Agency Recommends The Approval Of Thalidomide For The Treatment Of Rare Bone-Marrow Cancer
|
| Meeting on 21-24 January 2008, the Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that the benefits of Thalidomide Pharmion in combination with melphalan and prednisone outweigh its risks for the first-line treatment of multiple myeloma for patients over 65 years of age or who cannot be treated with high-dose chemothe...more |
|
Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study - Abstract
|
| Investigators were asked to provide the date of death or last follow-up for all participants who were alive in August 2003.
By March 2007, data on 310 additional deaths were obtained (total = 867 deaths). The survival benefit of D3P compared with MP has persisted with extended follow-up (P = .004). Median survival time was 19.2 months (95% CI, 17....more |
|
Know the signs of polymalgia rheumatica
|
| The symptoms tend to develop quickly, during a period of a few days or a week, and occasionally overnight. Difficulty raising the upper arms above the shoulders is common. Aching and stiffness are worse in the morning, and tend to improve gradually as the day progresses. Occasionally this aching occurs in joints such as those of the hand and feet.<...more |
|
Modulation of 11β-Hydroxysteroid Dehydrogenase (11βHSD) Activity Biomarkers and Pharmacokinetics of PF-00915275, a Selective 11βHSD1 Inhibitor
|
| Objective: Demonstrating inhibition of 11βHSD1 is challenging because there is no accessible way to directly assess the enzyme activity in vivo. Thus, it was proposed to assess the enzyme activity, in an indirect fashion, using two biomarker methods: the prednisolone generation study (conversion of oral prednisone to prednisolone in plasma) an...more |
|
Modified-Release Prednisone Reduces Morning Stiffness in Patients with Rheumatoid Arthritis (CAPRA-1 TRIAL)
|
| Circadian (day-night) rhythms of endogenous cortisol and anti-inflammatory protection are changed in patients with RA. A new-modified release delivery system has been developed which adapts the release of the administered glucocorticoid (prednisone) to the circadian rhythms of the disease symptoms, and improves the performance of the treatment.
Pr...more |
|
Thalomid® (Thalidomide) Prolongs Survival in Elderly Patients with Multiple Myeloma
|
| Melphalan/prednisone has been the reference treatment for newly diagnosed, elderly patients with multiple myeloma (MM). A previous study from the IFM (99-06) reported that the addition of Thalomid to standard MP improves progression-free and overall survival compared to either MP or MEL-100 and autologous stem cell support in newly diagnosed ...more |
|
|
